Abbott propoxyphene assay: evaluation and comparison of TDx FPIA and GC/MS methods.

J Anal Toxicol

Institut de Médecine Légale, Strasbourg, France.

Published: October 1993

This study evaluated the capability of the Abbott TDx assay to test for propoxyphene in urine and various biological samples, including tissues obtained from three fatal overdoses, by comparison to gas chromatography/mass spectrometry (GC/MS). First, within-run and between-run precision were determined using three control samples (200, 400, and 900 ng/mL) tested over a two-week period. Within-run coefficients of variation (CV) for the three controls were 1.4, 2.2, and 2.5%, respectively; the between-run CVs were 2.5, 3.1, and 4.0%, respectively. The cross-reactivity with norpropoxyphene, the major metabolite of propoxyphene, was concentration dependent and in the range of 29.3 to 92.6%. Propoxyphene and its metabolite were assayed in biological samples the same day using the Abbott TDx and GC/MS. Tissue preparations were analyzed by TDx without specimen pretreatment other than homogenization and dilution with saline. The TDx results were in accordance with the results obtained by GC/MS.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jat/17.4.222DOI Listing

Publication Analysis

Top Keywords

abbott tdx
8
biological samples
8
tdx gc/ms
8
tdx
5
abbott propoxyphene
4
propoxyphene assay
4
assay evaluation
4
evaluation comparison
4
comparison tdx
4
tdx fpia
4

Similar Publications

Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study.

J Clin Med

November 2021

Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University, Skłodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.

Background: Carbamazepine (CBZ) is a first-generation anticonvulsant drug. Hence, in certain cases, therapeutic drug monitoring (TDM) supports pharmacotherapy.

Methods: The presented research was based on a retrospective analysis including 710 ambulatory and hospitalized patients treated with CBZ between the years 1991 and 2011.

View Article and Find Full Text PDF

Objectives: Methotrexate requires therapeutic drug monitoring in oncology because of narrow therapeutic index, especially the metabolite 7-hydroxymethotrexate exhibits nephrotoxicity. The goal of this study was to evaluate different assays and their impact on clinical decisions.

Methods: Following routine measurement with Abbott TDxFLx® assay (MTX-TDX), 62 samples were analysed on Architect®i1000 (MTX-ARCHI), Xpand® (ARK/XPND), Indiko® (ARK/INDI), and HPLC (MTX-HPLC) as the reference method.

View Article and Find Full Text PDF

Therapeutic drug monitoring of digoxin-20 years of experience.

Pharmacol Rep

February 2018

Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.

Background: Digoxin is the oldest drug used in the pharmacotherapy of heart failure (HF). However, digoxin remains an important therapeutic option for patients with persistent symptoms of HF occurring despite the implementation of standard pharmacotherapy. Digoxin concentration serum (SCD) should equal 1-2ng/ml.

View Article and Find Full Text PDF

Analytical interference in the therapeutic drug monitoring of methotrexate.

Ann Biol Clin (Paris)

June 2016

Laboratoire de pharmacologie et toxicologie, Hôpital Maison Blanche, CHU de Reims, Reims, France, SFR Cap-Santé-EA3801-Université de Reims, Laboratoire de pharmacologie médicale, Faculté de médecine, Reims, France.

High-dose of methotrexate chemotherapy is used in the treatment of some tumors. It presents several side effects that required therapeutic drug monitoring, which is commonly performed on 24, 48 and 72h after the beginning of the methotrexate infusion. Treatment of overexposure to methotrexate is based on injection of carboxypeptidase G2, which specifically degrades methotrexate into inactive metabolite: DAMPA.

View Article and Find Full Text PDF

Background: High-dose methotrexate (HDMTX) is used in the treatment of certain malignancies, including leptomeningeal metastases, systemic non-Hodgkin lymphoma, acute lymphoblastic leukemia, and osteosarcoma. High circulating levels of methotrexate can cause severe myelosuppression. The present study aimed to examine the differences in plasma MTX concentrations measured by two immunoassay systems currently available in the Japanese market, a TDX/FLX analyzer and a TBA-25FR analyzer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!